S. Paulus

Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER‐medicare analysis

D. Hodge, A. Chanan-Khan, V. Roy, 2017, Cancer medicine.

Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities

A. Chanan-Khan, V. Roy, M. Temkit, 2018, Cancer.

Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells

A. Chanan-Khan, V. Roy, S. Ansell, 2016, Blood Cancer Journal.

Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment

Y. Asmann, A. Chanan-Khan, T. Caulfield, 2017, Blood Cancer Journal.

Targeting Bcl-2 Enhances the Anti-Tumor Effects of Lenalidomide and Dexamethasone in in Vitro and In Vivo Models of Multiple Myeloma

A. Chanan-Khan, V. Roy, A. Paulus, 2016 .

Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells

S. Ansell, A. Chanan-Khan, Liuyan Jiang, 2018, British journal of haematology.

Drug Resistance Alters CD38 Expression and in Vitro Response to Daratumumab in Waldenstrom Macroglobulinemia Cells

A. Chanan-Khan, S. Ansell, V. Roy, 2016 .